At a glance
ClinicalIndex Comparison RecordPhase 2Not Yet Recruiting· 60 target
Drug / intervention
ZG006biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study Evaluating the Preliminary Efficacy and Safety of ZG006 in Participants With Metastatic Neuroendocrine Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating ZG006 for Neuroendocrine Prostate Cancer. Not yet recruiting, targeting 60 participants across 1 site.
Detailed Summary
This is a multicenter, open-label Phase II study, aimed at exploring the preliminary efficacy and safety of ZG006 in patients with advanced metastatic NEPC who have previously failed standard treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuroendocrine Prostate Cancer
CountriesChina
Collaborators--
Timeline
Phase 2Not Yet Recruiting
202620272028
First PostedJun 2025
Enrollment StartAug 2025
TodayJul 2026
Primary CompletionDec 2027
First PostedJun 17, 2025
Enrollment StartAug 1, 2025
Primary CompletionDec 1, 2027
TodayJul 1, 2026
Enrollment to primary: 2.3 yearsPosted 1.0 years agoPrimary completion in 1.4 years
Interventions
ZG006biological
ZG006 will be administered as an intravenous (IV) infusion.